次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。順調なR&DやPL等の進捗・拡大の加速。笑。
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※SOSEI適時開示IR：最高財務責任者(CFO)の選任に関するお知らせ "2月1日付でAndrew Oakley氏" (1/19)
※米国特許出願(Heptares): Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor Agonists (1/19公開)
※Allergan Focuses on Alzheimer’s Symptoms as Treatment Eludes. (1/19)
※Biotech CFO joins drive to ‘build Sosei into a global presence’ (1/19)
※Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. "more effective" (1/19)
※SOSEIお知らせIR：JITSUBO社、開発品(循環器系疾患治療薬JIT-2001)の共同開発・ライセンス契約締結のお知らせ (1/20)
※SOSEI_HPパイプライン: 後発医薬品JIT-2005(代謝性疾患)、新規医薬品JIT-8012(消化器系疾患)を追加。
※Drug Profile: PLX PAD. (1/4, 1/12, 1/17, 1/20 update)
※Trial Profile: Phase I, AZD4635 (1/20 update)
※Novartis’s 4Q16 Estimates, Key Innovative Medicines Products: "Expected to Report Growth" (1/20)
※The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%. (1/23)
※バイオベンチャー株投資、究極のリスク回避ワザ!? "状況を再チェックするのが重要" (1/24)
※HeptaresTL: Giles Brown Talk: GPCR Structure-Based Drug Design: Discovery of Highly Selective M1 Agonists. (1/25)
※Novartis Q4 and FY 2016 Results (1/25)
・Ultibro Breezhaler/Utibron Neohaler (USD 90 million, +20% cc), FY (USD 363 million, +38% cc), Grow strongly by FLAME results and GOLD guidelines
・Seebri Breezhaler/Seebri Neohaler (USD 38 million, +9% cc), FY (USD 149 million, +2% cc)
・GOLD released updated 2017 guidelines for the management of COPD. First-line treatment with a drug from the LABA/LAMA class recommended
・The results of the pragmatic CRYSTAL study of Ultibro Breezhaler in COPD. These results further support the 2017 GOLD recommendations.
・New data from two head-to-head studies showed Utibron Neohaler provided clinically meaningful and comparable bronchodilation to Anoro in US. However,
・Progressing development of 13 potential blockbusters at Novartis. QVM149 (Asthma)
※Vectura: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt (1/25)
・Ultibro grow strongly, by the positive results of the FLAME and with further potential both from the recent change to the GOLD guidelines and the planned 2017 US launch.
・Further progress of the Novartis asthma triple programme QVM149, which is currently in Phase III with first planned submissions in 2019.
・The share is getting closer to its long-term support in weekly data, at JPY 12750, which offers good timing for buyers.
・Share prices are approaching a strong support area in daily data, which offers good timing for investors.
・・・
次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。順調なR&DやPL等の進捗・拡大の加速。笑。
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
・・・
※SOSEI適時開示IR：最高財務責任者(CFO)の選任に関するお知らせ "2月1日付でAndrew Oakley氏" (1/19)
※米国特許出願(Heptares): Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor Agonists (1/19公開)
※Allergan Focuses on Alzheimer’s Symptoms as Treatment Eludes. (1/19)
※Biotech CFO joins drive to ‘build Sosei into a global presence’ (1/19)
※Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. "more effective" (1/19)
※SOSEIお知らせIR：JITSUBO社、開発品(循環器系疾患治療薬JIT-2001)の共同開発・ライセンス契約締結のお知らせ (1/20)
※SOSEI_HPパイプライン: 後発医薬品JIT-2005(代謝性疾患)、新規医薬品JIT-8012(消化器系疾患)を追加。
※Drug Profile: PLX PAD. (1/4, 1/12, 1/17, 1/20 update)
※Trial Profile: Phase I, AZD4635 (1/20 update)
※Novartis’s 4Q16 Estimates, Key Innovative Medicines Products: "Expected to Report Growth" (1/20)
※The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%. (1/23)
※バイオベンチャー株投資、究極のリスク回避ワザ!? "状況を再チェックするのが重要" (1/24)
※HeptaresTL: Giles Brown Talk: GPCR Structure-Based Drug Design: Discovery of Highly Selective M1 Agonists. (1/25)
※欧州特許出願(Heptares): Muscarinic Receptor Agonists. (1/25公開)
※Novartis Q4 and FY 2016 Results (1/25)
・Ultibro Breezhaler/Utibron Neohaler (USD 90 million, +20% cc), FY (USD 363 million, +38% cc), Grow strongly by FLAME results and GOLD guidelines
・Seebri Breezhaler/Seebri Neohaler (USD 38 million, +9% cc), FY (USD 149 million, +2% cc)
・GOLD released updated 2017 guidelines for the management of COPD. First-line treatment with a drug from the LABA/LAMA class recommended
・The results of the pragmatic CRYSTAL study of Ultibro Breezhaler in COPD. These results further support the 2017 GOLD recommendations.
・New data from two head-to-head studies showed Utibron Neohaler provided clinically meaningful and comparable bronchodilation to Anoro in US. However,
・Progressing development of 13 potential blockbusters at Novartis. QVM149 (Asthma)
※Vectura: Seebri / Ultibro Breezhaler 2016 sales reach $512 million triggering $5 million milestone receipt (1/25)
・Ultibro grow strongly, by the positive results of the FLAME and with further potential both from the recent change to the GOLD guidelines and the planned 2017 US launch.
・Further progress of the Novartis asthma triple programme QVM149, which is currently in Phase III with first planned submissions in 2019.
※SOSEIお知らせIR待ち (1/26)
Event:
・・・
※2017年(平成29年)3月期 第3四半期決算発表、2017年2月10日
・・・
下期、R&D等の拡充・進捗は着実に進み、年度期末に向けての次なる展開・進捗が楽しみですね。笑。
成長相場の動向：上抜け圏にて強気相場後の時間軸調整は良好。控える材料と共に強気相場待ち。笑。
2011/12/30 終値_1271 売残高 ____0 買残高 _518100 大納会 ・(2012/1/4 大発会 1292)
2012/12/21 終値_2093 売残高 __100 買残高 _653600 ・(2012/12/28 大納会 2087) (2013/1/4 大発会 2061)
2013/12/20 終値_4045 売残高 28500 買残高 _833300 ・(2013/12/30 大納会 4315) (2014/1/6 大発会 4415)
2014/12/19 終値_4355 売残高 __700 買残高 1691900 ・(2014/12/30 大納会 4370) (2015/1/5 大発会 4280)
2015/12/25 終値_9670 売残高 _7500 買残高 2282200 ・(2015/12/30 大納会 9950) (2016/1/4 大発会 10300)
2016/12/30 終値13450 売残高 __300 買残高 2920000(-126600)大納会 ・(5/9最高値26180、6/24安値12960、11/9安値12510、12/8安値12470)
_1/_6 (終値14030) 売残高 __300 買残高 2907100(_-12900) ・(2017/1/4 大発会 13720)
_1/13 (終値13520) 売残高 __300 買残高 2881000(_-26100)
_1/20 (終値13190) 売残高 __100 買残高 2901800(_+20800)
_1/25 (終値13360) 5日線乖離(+1.09%) 25日線乖離( +0.13％) 75日乖離(_-8.36％) 200日線乖離(-21.56％)
※機関の空売り残高情報。笑。ttp://karauri.net/4565/
※Sosei: Technical Analysis Charts (Week), Analysis.
・ttp://www.zonebourse.com/zbcache/charts/ObjectChart.aspx?Name=6814799&Type=Custom&Intraday=1&Width=805&Height=650&Cycle=WEEK1&Duration=50&Render=Candle&ShowName=0&Company=4Traders_us
・The share is getting closer to its long-term support in weekly data, at JPY 12750, which offers good timing for buyers.
・Share prices are approaching a strong support area in daily data, which offers good timing for investors.
・・・
時間軸調整後の次なる展開も楽しみです。笑。